Efficacy and toxicity of 2-chlorodeoxyadenosine (cladribine)—2h infusion for 5 days—as first-line treatment for advanced low grade non-Hodgkin’s lymphoma
- 1 September 1998
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 34 (10) , 1560-1564
- https://doi.org/10.1016/s0959-8049(98)00140-3
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin's lymphomaAnnals of Oncology, 1996
- 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphomaBlood, 1995
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytesAdvances in Enzyme Regulation, 1988
- Reporting outcomes in Hodgkin's disease and lymphoma.Journal of Clinical Oncology, 1987
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasNew England Journal of Medicine, 1984
- Reporting results of cancer treatmentCancer, 1981
- Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.Proceedings of the National Academy of Sciences, 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958